Long-Term–Benefit Approach to Determine Statin Eligibility?

Equations that look at 30-year benefit from statin treatment as primary prevention identified more statin-eligible individuals.

Although statins are the cornerstone for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD), determining statin eligibility in primary prevention remains controversial, with 10-year risk assessments possibly failing to identify young individuals with elevated LDL levels who would benefit from statins. To compare various methods of computing risk, researchers used cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) on 1688 adults without ASCVD or diabetes and not on statins (age range, 40–60); this study population was representative of almost 57 million U.S. individuals.

The investigators compared the number of individuals recommended for statin therapy according to American Heart A…

Reviewing Author

Fatima Rodriguez, MD, MPH

Disclosures

Consultant/Advisory BoardNovoNordisk; HealthPals; Novartis; Amgen

EquityHealthPals; Carta

Grant/Research SupportNational Institutes of Health/National Heart, Lung, and Blood Institute; American Heart Association–Robert Wood Johnson Foundation

Editorial BoardsCardiology and Therapy